EphA2 Marker Sorting for Mesenchymal Stem Cell Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively distinguish mesenchymal stem cells (MSCs) from fibroblasts in primary cultures derived from placenta-related tissues due to the lack of specific cell surface markers, leading to contamination and impurity in MSC populations.
Innovation Solution
The use of EphA2 as a surface marker for sorting MSCs in primary cultures from placenta-related tissues, enabling the differentiation and isolation of pure MSC populations, particularly from fibroblasts, through techniques like antibody-based or nucleotide-based isolation methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional cell culture methods are used without specific markers, then the isolation procedure is simple, but the MSC population purity is low due to fibroblast contamination
Solution Approach 1:
The patent changes the parameter of cell surface marker expression profile to distinguish MSCs from fibroblasts. By identifying that MSCs express CD73, CD90, and CD105 while fibroblasts express vimentin and show different marker patterns, the method enables precise sorting and purification of MSC populations without complex procedural changes
Solution Approach 2:
The patent replaces mechanical/manual cell separation methods with marker-based identification and sorting approaches. By using specific surface markers (CD73, CD90, CD105 for MSCs; vimentin for fibroblasts) detected through flow cytometry or immunostaining, the system achieves automated, precise cell population separation without complex mechanical manipulation
2Measurement precision
If functional properties analysis is used to distinguish MSCs from fibroblasts, then the distinction accuracy is high, but the time and resources required are excessive
Solution Approach 1:
The patent performs preliminary characterization of cell surface markers on primary cultured cells immediately after isolation. By establishing the marker expression profile (CD73+, CD90+, CD105+ for MSCs) early in the culture process, the method enables rapid identification and sorting of MSCs before functional assays are performed, saving significant time and resources
Solution Approach 2:
The patent segments the cell population identification process into distinct marker-based steps: first identifying MSCs by CD73, CD90, and CD105 expression, then separately identifying fibroblasts by vimentin expression. This segmented approach allows parallel processing and rapid distinction without requiring complete functional analysis of all cells
3Ease of manufacture
If placenta-derived tissues are used as MSC source, then the isolation is non-invasive and ethically acceptable, but the cell composition is heterogeneous and contamination risk is high
Solution Approach 1:
The patent changes the parameter of cell surface marker expression to identify and sort pure MSC populations from heterogeneous placenta-derived tissues. By detecting specific marker combinations (CD73+, CD90+, CD105+ for MSCs versus vimentin+ for fibroblasts), the method achieves high purity MSC isolation while maintaining the non-invasive advantage of using placental tissues
Solution Approach 2:
The patent extracts the desired MSC population from the heterogeneous placenta-derived cell mixture by using marker-based identification and sorting. By taking out only the cells expressing the specific MSC marker profile (CD73, CD90, CD105) and excluding vimentin-expressing fibroblasts, the method achieves pure MSC cultures from complex tissue sources
Data Source
AI summary
A method of distinguishing mesenchymal stem cells (MSCs) in a primary culture of cells derived from a placenta-related tissue is provided. Also provided is a method of increasing the purity of MSC population in a primary culture of cells derived from a placenta-related tissue. Further provided is a method of isolating a MSC population which is more responsive in an inflammatory environment. Said methods each comprise a step of sorting the cells by a marker of EphA2.